{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:05:14Z","timestamp":1784613914725,"version":"3.55.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurological disorders are associated with considerable morbidity and healthcare impact. Therapeutic plasma exchange (TPE) is an intervention that removes pathogenic antibodies, immune complexes, and other plasma constituents from circulation. Previous studies have suggested that TPE could be associated with improved outcomes in selected neurological disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate functional outcomes following therapeutic plasma exchange in patients with selected neurological disorders at National Guard Health Affairs (NGHA) in Jeddah, Saudi Arabia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study analyzes 133 patients diagnosed with various neurological disorders who received TPE between August 2015 and December 2022 at NGHA. Diagnoses included multiple sclerosis (MS), myasthenia gravis (MG), Guillain-Barr\u00e9 syndrome (GBS), neuromyelitis optica spectrum disorder (NMOSD), chronic inflammatory demyelinating polyneuropathy (CIDP), autoimmune encephalitis (AE), and other neurological conditions including amyotrophic lateral sclerosis (ALS), transverse myelitis, cerebellar ataxia, paraneoplastic neurologic syndrome, polymyositis, and central nervous system (CNS) infections. The effectiveness of TPE was assessed using the Modified Rankin Scale (mRS) before and 90\u202fdays following the final TPE session. Statistical analysis included Wilcoxon signed-rank tests and Mann\u2013Whitney U test, with significance set at (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Significant improvements in mRS scores were observed following TPE for MS, MG, and GBS (all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), as well as for NMOSD (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.008), CIDP (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.007), and AE (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.018), but not in other neurological disorders (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.234). Overall mortality was 6.8%, with no TPE-related deaths. Comorbidities among deceased patients included hypertension, diabetes mellitus, malignancy, chronic kidney disease, and cardiovascular disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TPE was associated with improved functional outcomes in selected neurological disorders. Comorbidities were common among patients with poorer outcomes. Due to the retrospective design and potential confounding factors, causal inferences cannot be established. Further prospective studies are warranted to evaluate the role of TPE and optimize patient selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1876331","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:36:00Z","timestamp":1784612160000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of therapeutic plasma exchange with functional outcomes in selected neurological disorders: a retrospective cohort study from a single tertiary center in Saudi Arabia"],"prefix":"10.3389","volume":"17","author":[{"given":"Fatemah I.","family":"Ammar","sequence":"first","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences","place":["Jeddah, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa","family":"Aljahdali","sequence":"additional","affiliation":[{"name":"King Abdullah International Medical Research Center","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Alshrif","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences","place":["Jeddah, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Alshareef","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences","place":["Jeddah, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Faidah","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences","place":["Jeddah, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Almohammadi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ministry of National Guard Health Affairs","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seraj","family":"Makkawi","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences","place":["Jeddah, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Jeddah, Saudi Arabia"]},{"name":"Department of Neurology, Ministry of National Guard Health Affairs","place":["Jeddah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1525-139X.2011.01023.x","article-title":"Evidence-based review of therapeutic plasma exchange in neurological disorders","volume":"25","author":"Chhibber","year":"2012","journal-title":"InSemin Dial"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/0972-2327.144301","article-title":"Plasmapheresis in neurological disorders: experience from a tertiary care hospital in South India","volume":"18","author":"Gafoor","year":"2015","journal-title":"Ann Indian Acad Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.20471\/acc.2019.58.04.08","article-title":"Therapeutic plasma exchange and double filtration plasmapheresis in severe neuroimmune disorders","volume":"58","author":"Roman-Filip","year":"2019","journal-title":"Acta Clin Croat"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"EC35","DOI":"10.7860\/JCDR\/2017\/27073.10480","article-title":"Therapeutic plasma exchange-an emerging treatment modality in patients with neurologic and non-neurologic diseases","volume":"11","author":"Bobati","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/practneurol-2019-002336","article-title":"Plasma exchange in neurological disease","volume":"20","author":"Osman","year":"2020","journal-title":"Pract Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.18502\/ijnl.v19i1.3282","article-title":"Complications of therapeutic plasma exchange in patients with neurological disorders","volume":"19","author":"Afzali","year":"2020","journal-title":"Curr J Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12883-020-1629-3","article-title":"Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study","volume":"20","author":"Aljumah","year":"2020","journal-title":"BMC Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e20765","DOI":"10.7759\/cureus.20765","article-title":"Clinical presentation, management, and outcome in patients with myasthenia gravis: a retrospective study from two tertiary care centers in Saudi Arabia","volume":"13","author":"Algahtani","year":"2021","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.12659\/MSM.894119","article-title":"Therapeutic plasma exchange in multiple sclerosis patients with abolished interferon-beta bioavailability","volume":"21","author":"Giedraitiene","year":"2015","journal-title":"Med Sci Monit"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice \u2013 evidence-based approach from the writing Committee of the American Society for apheresis: the ninth special issue","volume":"38","author":"Connelly-Smith","year":"2023","journal-title":"J Clin Apher"},{"key":"ref12","volume-title":"StatPearls","author":"Sergent","year":"2022"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"17562864231154306","DOI":"10.1177\/17562864231154306","article-title":"Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature review","volume":"16","author":"Pinto","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"100468","DOI":"10.1016\/j.ensci.2023.100468","article-title":"Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barr\u00e9 syndrome (GBS) in patients with severe symptoms: a systematic review and meta-analysis. eNeurologicalSci","volume":"31","author":"Zaki","year":"2023"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1111\/ene.16073","article-title":"European academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome","volume":"30","author":"Van Doorn","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5201206","DOI":"10.1155\/2020\/3484659","article-title":"Therapeutic plasma exchange as a treatment for autoimmune neurological disease","volume":"2020","author":"Nieto-Aristiz\u00e1bal","year":"2020","journal-title":"Autoimmune Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3389\/fimmu.2019.01076","article-title":"Sex hormones and gender differences in immune responses","volume":"10","author":"Ortona","year":"2019","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e178722","DOI":"10.1172\/JCI178722","article-title":"Estimation of prevalence of autoimmune diseases in the United States using electronic health record data","volume":"135","author":"Abend","year":"2024","journal-title":"J Clin Invest"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.20471\/acc.2018.57.02.17","article-title":"Multiple sclerosis: new aspects of immunopathogenesis","volume":"57","author":"Lazibat","year":"2018","journal-title":"Acta Clin Croat"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/antib12030050","article-title":"Diagnosis and treatment of paraneoplastic neurologic syndromes. Antibodies","volume":"12","author":"Chiu","year":"2023"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1876331\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:36:01Z","timestamp":1784612161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1876331\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":20,"alternative-id":["10.3389\/fneur.2026.1876331"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1876331","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1876331"}}